Baupost Group LLC Sells Last of Facet Biotech (FACT) Stake
Is Facet Biotech Corporation late reporting EU clinical trials?
Покупка «Facet Biotech» так и не состоялась | Щотижневик АПТЕКА
Untitled
SECURITIES AND EXCHANGE COMMISSION SCHEDULE TO/A Facet Biotech Corporation Amber Acquisition Inc. Abbott Laboratories
Anunciados los resultados del estudio en Fase 3 de Daclizumab para la EM – BLOG ESCLEROSIS MULTIPLE @susosantiago
FACET BIOTECH (A1176：ﾅｽﾀﾞｯｸ市場)」 を保有されている投資家の皆様へ － 公開買付の中止
Facet's climbing share price points to growing investor confidence | Evaluate
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Form 8-K PDL BioPharma, Inc.
NB Capital
Clients | Damianakes Communications
Sameer Syed - Data Entry Clerk - Facet Biotech | LinkedIn
John Smith - Director Of Special Projects - Facet Biotech | LinkedIn
BVF bags trophy in Abbott-Facet deal - San Francisco Business Times
Facet Biotech: An Intriguing Activist Play | Seeking Alpha
Biotech spinoff Facet starts life $400M richer - San Francisco Business Times
SEC Filing | Biogen
Biogen Idec and Facet—Following the Money
g299861mmi007.gif
FACET BIOTECH CORP - FORM 8-K - EX-99.1 - February 9, 2010
Abbott outbids Biogen for Facet's multiple sclerosis antibody | Nature Biotechnology
Facet Biotech - Crunchbase Company Profile & Funding
